Zegomib

Zegomib (Bortezomib) is a prescription medication used in cancer treatment. Administered intravenously, it belongs to the proteasome inhibitor class. This overview covers general uses and handling notes for informational purposes only.

Zegomib is commonly prescribed to treat certain types of cancer, including multiple myeloma and mantle cell lymphoma. It works by slowing or stopping the growth of cancer cells. Patients often use it as part of a broader chemotherapy regimen. Always consult a healthcare provider for personalized treatment plans.

Zegomib may cause side effects such as fatigue, nausea, or reduced blood cell counts. Some individuals experience peripheral neuropathy, which can include tingling or numbness in the hands or feet. These effects vary by patient and are typically monitored during treatment.

Zegomib should be handled with care by healthcare professionals due to its potency. Patients must report any signs of infection, bleeding, or unusual symptoms to their doctor promptly. Avoid close contact with others who are sick during treatment.

Zegomib can interact with other medications, including certain antivirals, antifungals, and blood pressure drugs. Alcohol and grapefruit products may also affect its metabolism. Always inform your healthcare provider about all medications and supplements you are taking.